Cancerous disease modifying antibodies

Details Cancerous disease modifying antibodies Cancerous disease modifying antibodies

2006-07-31

2008-11-25

Blanchard, David J. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S388100, C530S388800, C530S391100, C424S133100, C424S141100, C424S155100, C424S174100, C435S007100

Reexamination Certificate

active

07456258

ABSTRACT:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

REFERENCES:
patent: 4433059 (1984-02-01), Chang et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 7189825 (2007-03-01), Young et al.
patent: 2005/0191305 (2005-09-01), Young et al.
patent: 57621/90 (1991-01-01), None
patent: 2456077 (2003-12-01), None
patent: 2557091 (2005-09-01), None
patent: 2557093 (2005-09-01), None
patent: 0266032 (1988-05-01), None
patent: WO9311161 (1993-06-01), None
patent: WO0034317 (2000-06-01), None
patent: WO2004065420 (2004-08-01), None
patent: WO2004065421 (2004-08-01), None
patent: WO2005012361 (2005-02-01), None
L. Belanger et al, “Enzyme-linked immunoassay for alpha-fetoprotein by competitive and sandwich procedures”, Clinica Chimica Acta, 48:15-18 (1973).
M. Bendandi et al, “Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma”, Nature Medicine, 5(10):1171-1177 (Oct. 1999).
P. Capel et al, “Heterogeneity of human IgG Fc receptors”, Immunomethods, 4:25-34 (1994).
C. Chothia et al, “Canonical structures for the hypervariable regions of immunoglobulins”, J. Mol. Biol., 196:901-917 (1987).
T. Clackson et al, “Making antibody fragments using phage display libraries”, Nature, 352-624-628 (Aug. 1991).
R. Clynes et al, “Fc receptors are required in passive and active immunity to melanoma”, Proc. Natl. Acad. Sci. USA, 95:652-656 (Jan. 1998).
S. Eckhardt et al, “Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds”, ASCO Educational Book, 39th Annual Meeting, pp. 209 (2003).
B. Froehler et al, “Synthesis of DNA via deoxynucleoside H-phosphonate intermediates”, Nucleic Acids Research, 14(13):5399-5407 (1986).
H. Gazzano-Santoro et al, “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody”, J. Immunol. Methods, 202:163-171 (1997).
R. Guyer et al, “Immunoglobin binding by mouse intestinal epithelial cell receptors”, J. Immunol., 117(2):587-593.
M. De Haas et al, “Review articles: FCy receptors of phagocytes”, J. Lab Clin. Med., 126:330-341 (1995).
S. Hirschfeld et al, “Oncology drug development: United States Food and Drug Administration Perspective”, Critical Reviews in Oncology/Hematology, 42:137-143 (2002).
P. Holliger et al, “Diabodies: small bivalent and bispecific antibody fragments”, Proc. Natl. Acad. Sci. USA, 90:6444-6448 (Jul. 1993).
E. Kabat et al, “Sequences of proteins of immunological interest”, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).
J. Kim et al, “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor”, Eur. J. Immunol., 24:2429-2434 (1994).
G. Kohler et al, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, 256:495-497 (Aug. 1975).
J. Marks et al, “By-passing immunization human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol., 222:581-597 (1991).
M. Daeron, “Fc receptor biology”, Annu. Rev. Immunol., 15:203-234 (1997).
S. Morrison et al, “Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains”, Proc. Natl. Acad. Sci. USA, 81:6851-6855 (Nov. 1984).
A. Pluckthun, “Antibodies fromEscherichia coli”, Handbook of Experimental Pharmacology, vol. 113, Chapter 11, pp. 269-315, Springer-Verlag, New York (1994).
M. Schuster et al, “Cancer immunotherapy”, Biotechnology Journal, 1:138-147 (2006).
P. Therasse et al, “New guidelines to evaluate the response to treatment in solid tumors”, J. Natl. Cancer Inst., 92:205-216 (2000).
J. Rubinstein et al, “Use of phage display and high-density screening for the isolation of an antibody against the 51-kDa subunit of complex I”, Analytical Biochemistry, 314:294-300 (2003).
J. Ravetch et al, “Fc receptors”, Annu. Rev. Immunol., 9:457-492 (1991).

Affiliated with

Also associated with

Rating

Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4023970